Martin Kaul

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 883 citations

Life Sciences, Dermatology, Immunology +10

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

J.‐H. Saurat, G Stingl, Louis Dubertret et al. · British Journal of Dermatology · 2007 · 722 citations

Medicine, Dermatology, Pharmacotherapy +9

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

L.B.A. van de Putte, Michel Malaise, J Sany et al. · Annals of the Rheumatic Diseases · 2004 · 620 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels*

Edward A. Panacek, John C. Marshall, Timothy E. Albertson et al. · Critical Care Medicine · 2004 · 384 citations

Veterinary Medicine, Immunology, Pharmacotherapy +16

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock

Konrad Reinhart, Carola Wiegand-Lohnert, Friedrich Grimminger et al. · Critical Care Medicine · 1996 · 364 citations

Veterinary Medicine, Immunology, Pharmacology +13